AMI Asset Management
CYTK icon

AMI Asset Management’s Cytokinetics CYTK Stock Holding History

AMI Asset Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$975K Buy
14,800
+539
+4% +$41.1K 0.06% 56
2026
Q2 		$1.21M Sell
14,261
-555
-4% -$39.8K 0.07% 45
2026
Q1 		$977K Buy
14,816
+536
+4% +$34.1K 0.06% 57
2025
Q4 		$907K Sell
14,280
-1,003
-7% -$62.4K 0.05% 62
2025
Q3 		$840K Buy
+15,283
New +$630K 0.05% 67

Other funds holding CYTK

State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.8B AUM 33.92% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

AMI Asset Management's CYTK Position: Q3 2026 in Review

AMI Asset Management increased its Cytokinetics (CYTK) stake by 3.8% in Q3 2026, buying an estimated $41.1K and bringing the position to 14,800 shares worth $975K. The position accounts for 0.06% of the portfolio, ranked #56.

AMI Asset Management first reported a position in CYTK in Q3 2025 and has held it in 5 quarters since. The position peaked at $1.21M in Q2 2026. 282 funds tracked by Wall St. Rank hold CYTK as of Q3 2026.

  • AMI Asset Management held 14,800 shares of Cytokinetics worth $975K as of Q3 2026.
  • AMI Asset Management bought 539 Cytokinetics shares in Q3 2026, an estimated $41.1K.
  • Cytokinetics made up 0.06% of AMI Asset Management's portfolio in Q3 2026, its #56 holding.
  • AMI Asset Management first reported a position in Cytokinetics in Q3 2025 and has held it in 5 quarters since.
  • AMI Asset Management's Cytokinetics position peaked at $1.21M in Q2 2026.
  • 282 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2026.

Based on AMI Asset Management's 13F filing for Q3 2026, filed 20 Oct 2026.